A Randomized Double-Blind Placebo-Controlled Trial to Evaluate Prophylactic Effect of Traditional Chinese Medicine Supplementing Qi and Hemostasis Formula on Gastrointestinal Bleeding after Percutaneous Coronary Intervention in Patients at High Risks.
Chenhao ZhangChaolian HuangXiaolin KongGuannan LiuNing LiJie LiuZongyao ZhangDawei YangChunling LiangJie WangPublished in: Evidence-based complementary and alternative medicine : eCAM (2018)
(1) Supplementing Qi and hemostasis formula is equal to Pantoprazole Sodium Enteric-Coated Capsule in hemostasis and gastric mucosal protection; (2) supplementing Qi and hemostasis formula is superior to Pantoprazole Sodium Enteric-Coated Capsule in improving TCM syndrome manifestation possibly through the multitarget mechanism; (3) interference on clopidogrel of supplementing Qi and hemostasis formula might be much less than Pantoprazole Sodium Enteric-Coated Capsule due to the potential CYP450-independent mechanism. This trial is registered with ChiCTR1800014485.
Keyphrases
- percutaneous coronary intervention
- double blind
- human milk
- acute coronary syndrome
- study protocol
- clinical trial
- antiplatelet therapy
- coronary artery disease
- phase iii
- st segment elevation myocardial infarction
- phase ii
- st elevation myocardial infarction
- coronary artery bypass grafting
- atrial fibrillation
- heart failure
- coronary artery bypass